National Bank of Canada
CRVS icon

National Bank of Canada’s Corvus Pharmaceuticals CRVS Stock Holding History

National Bank of Canada’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.72K Buy
+115
New +$1.6K ﹤0.01% 2721

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

National Bank of Canada's CRVS Position: Q2 2026 in Review

National Bank of Canada opened a new position in Corvus Pharmaceuticals (CRVS) in Q2 2026: 115 shares worth $1.72K. The stake represents ﹤0.01% of the portfolio and ranks #2721 among its holdings.

174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • National Bank of Canada held 115 shares of Corvus Pharmaceuticals worth $1.72K as of Q2 2026.
  • Corvus Pharmaceuticals was a new National Bank of Canada position in Q2 2026.
  • Corvus Pharmaceuticals made up ﹤0.01% of National Bank of Canada's portfolio in Q2 2026, its #2721 holding.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on National Bank of Canada's 13F filing for Q2 2026, filed 10 Aug 2026.